Mepolizumab Fails in a Phase II Trial

Allergy & Clinical Immunology

Mepolizumab, an IL-5 inhibitor, failed to alleviate moderate persistent asthma symptoms in a phase II trial of patients resistant to corticosteroids. References and Resources Flood-Page P, Swenson C,…